Co-Diagnostics, Inc. to Present at the Lytham Partners Virtual Investor Conference on November 30, 2017 at 2:00 p.m. ET
November 22 2017 - 3:11PM
Business Wire
Management to Review Investor Presentation
and Conduct Q&A; Replay Available on Demand
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular
diagnostics company with a unique, proprietary platform for the
development of diagnostic tests, announced that Dwight Egan,
chief executive officer of Co-Diagnostics, will present at the
Lytham Partners Virtual Investor Conference on Thursday, November
30, 2017 at 2:00 p.m. ET (11:00 a.m. PT). The conference is a
virtual event available over the internet, and interested parties
may participate by following any of the links below at the time of
the conference.
Event: Lytham Partners Virtual Investor Conference
Date: November 30, 2017 Time:
2:00 p.m. ET / 11:00 a.m. PT
Webcast:
http://ir.codiagnostics.com/events-and-presentations
or http://www.lythampartners.com/vic.aspx, or by
accessing the link here.
Interested parties around the world may view the live investor
presentation and ask the speakers questions in real time.
A replay of the presentation will be available on demand
following the conclusion of the live event at
http://ir.codiagnostics.com/events-and-presentations or
http://www.lythampartners.com/vic.aspx, or by accessing the link
here.
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that has developed and intends to manufacture
and sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or RNA),
and to sell diagnostic equipment from other manufacturers as
self-contained lab systems.
Forward-Looking Statements
With the exception of historical information, the content in
this press release and the virtual investor conference referred to
in this communication, may contain “forward looking statements”
that are made pursuant to the Safe Harbor Provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as “believes,”
“expects,” “estimates,” “intends,” “may,” “plans,” “will” and
similar expressions, or the negative of these words. Such
forward-looking statements are based on facts and conditions as
they exist at the time such statements are made and predictions as
to future facts and conditions. These statements are based on
management’s current expectations and are subject to uncertainty
and changes in circumstances. Investors are cautioned that
forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the statements
made. Readers of this press release are cautioned not to place
undue reliance on any forward-looking statements. Risks,
uncertainties and other factors are discussed in the Company’s
filings with the U.S. Securities and Exchange Commission on Annual
Report Form 10-K, Quarterly Reports on Form 10-Q and Current
Reports on Form 8-K. The Company disclaims any obligation to update
its forward-looking relationships.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171122005596/en/
Company Contact:Co-Diagnostics, Inc.Andrew Benson,
Investor
Relations801-438-1036investors@codiagnostics.comorInvestor
Contact:Lytham PartnersJoe Diaz, Robert Blum, Joe
Dorame602-889-9700codx@lythampartners.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Sep 2023 to Sep 2024